Search Results for:Carl O'Donnell

SoftBank’s Son says to continue with deals despite trade jitters

Son is optimistic that U.S. President Donald Trump’s escalation of trade disputes and heightened scrutiny of foreign investments would not affect the Japanese firm’s prolific deal-making.


SoftBank CEO running out of time to clinch Sprint-T-Mobile merger

This is the companies’ third attempt to clinch a deal in the last four years.


US drugstore chain CVS Health to acquire insurer Aetna for $69b in year’s largest acquisition

The deal comes after Aetna’s $37 billion plan to acquire smaller U.S. health insurance peer Humana Inc  was blocked in January by a U.S. federal judge over antitrust concerns.


US pension fund CalPERS mulls changes in PE investing strategy

The move could result in slashing payments to fund managers


GIC, Abu Dhabi fund in talks to buy stake in US clinical trials firm

A deal could value the entire company at over $9 billion.


Starwood in talks on raising initial bid for Milestone REIT

The earlier agreed deal value was $1.3 billion.


Pfizer’s Medivation buy seen prescribing more biotech M&A

Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company’s growing oncology roster. Medivation shares jumped nearly 20 percent to close at $80.42, just shy of the offer… Read more »


Specialty drugmaker Endo explores asset sales

Specialty pharmaceutical company Endo International Plc has held discussions with private equity firms about potential asset sales as it seeks to reduce its more than $8 billion debt pile, according to people familiar with the matter. The move underscores the challenges facing the Dublin-based company, which has seen its shares drop… Read more »


Mega deals morph into mega problems for Wall Street

If 2015 was a dream year for Wall Street’s top dealmakers, 2016 is starting to take a nightmarish turn.


New US inversion rules threatens $160b Pfizer-Allergan merger

The U.S. Treasury Department took new steps to curb tax-avoiding corporate “inversions,” with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.